Tag archive for ‘Servier and omecamtiv mecarbil’
Cytokinetics; Amgen and Servier Announce Decision to Move Omecamtiv Mecarbil into Phase 3 (CYTK, Buy, $12.07)
Amgen issued a press release today in which it announced that Servier had decided to exercise its option to commercialize omecamtiv mecarbil in chronic heart failure in Europe, Russia and certain other territories. The companies announced that the Phase 3 program of omecamtiv mecarbil will move forward in collaboration with Cytokinetics. I think that the gating […]